News Releases

Baker Botts Advises Novartis on Sale of Sandoz Generic Assets to Aurobindo Pharma

News Release
Baker Botts L.L.P. is representing Novartis on the U.S. antitrust clearance of its sale of its Sandoz division’s U.S. dermatology business and generic U.S. oral solids portfolio to Aurobindo Pharma U.S.A., Inc.. The parties announced the transaction on September 5, 2018. The Novartis internal antitrust team on the transaction includes Susan Jones (Head Antitrust Legal, Novartis AG) and Ryan Foley (Sr. Corporate Counsel, Antitrust Americas).

The Baker Botts team is led by partners Steve Weissman and Michael Perry, who are supported by associates Matt Adler and Tim Singer. All are in the firm’s antitrust practice group in Washington, DC.

 

# # # 

About Baker Botts L.L.P.
Baker Botts is an international law firm of approximately 725 lawyers practicing throughout a network of 14 offices around the globe. Based on our experience and knowledge of our clients’ industries, we are recognized as a leading firm in the energy and technology sectors. Throughout our 178-year history, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit BakerBotts.com.

Read More

Related Professionals